Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC
We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing diagnostics for leptomeningeal metastases (LM) and other central nervous system (CNS) cancers.
In addition, we are pleased to welcome Dr. Marc Hedrick, Mr. Rick Hawkins, and Mr. Russell Bradley to the CNSide Board of Directors, further strengthening the leadership team. Additionally, Dr. Jonathan Stein has been named CNSide Medical Director, bringing his expertise to help guide the company’s clinical and diagnostic advancements.
These strategic appointments underscore Plus Therapeutics’ commitment to developing innovative diagnostic and therapeutic solutions for patients facing complex and life-threatening CNS cancers. With a strong leadership team in place, CNSide Diagnostics, LLC, is well-positioned to accelerate its pivotal trial development and bring cutting-edge diagnostics to patients in need.
📢 Read the full Press Release: Click here
#Leadership #OncologyResearch #NeuroOncology #CNSCancer #CancerDiagnostics #MedicalInnovation #PSTV
Recent Comments